Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 2001 Jul;91(7):1019–1024. doi: 10.2105/ajph.91.7.1019

The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals.

R S Janssen 1, D R Holtgrave 1, R O Valdiserri 1, M Shepherd 1, H D Gayle 1, K M De Cock 1
PMCID: PMC1446705  PMID: 11441723

Abstract

In the United States, HIV prevention programs have historically tailored activities for specific groups primarily on the basis of behavioral risk factors and demographic characteristics. Through the Serostatus Approach to Fighting the Epidemic (SAFE), the Centers for Disease Control and Prevention is now expanding prevention programs, especially for individuals with HIV, to reduce the risk of transmission as a supplement to current programs that primarily focus on reducing the risk of acquisition of the virus. For individuals with HIV, SAFE comprises action steps that focus on diagnosing all HIV-infected persons, linking them to appropriate high-quality care and prevention services, helping them adhere to treatment regimens, and supporting them in adopting and sustaining HIV risk reduction behavior. SAFE couple a traditional infectious disease control focus on the infected person with behavioral interventions that have been standard for HIV prevention programs.

Full Text

The Full Text of this article is available as a PDF (121.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. E., Wilson R. W., Barker P., Doll L., Jones T. S., Holtgrave D. Prevalence of sexual and drug-related HIV risk behaviors in the U.S. adult population: results of the 1996 National Household Survey on Drug Abuse. J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):148–156. [PubMed] [Google Scholar]
  2. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., Tsay J., Ip J., Farthing C., Limoli K. HIV-1 drug resistance in newly infected individuals. JAMA. 1999 Sep 22;282(12):1135–1141. doi: 10.1001/jama.282.12.1135. [DOI] [PubMed] [Google Scholar]
  3. Bozzette S. A., Berry S. H., Duan N., Frankel M. R., Leibowitz A. A., Lefkowitz D., Emmons C. A., Senterfitt J. W., Berk M. L., Morton S. C. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998 Dec 24;339(26):1897–1904. doi: 10.1056/NEJM199812243392606. [DOI] [PubMed] [Google Scholar]
  4. Busch M. P., Operskalski E. A., Mosley J. W., Lee T. H., Henrard D., Herman S., Sachs D. H., Harris M., Huang W., Stram D. O. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis. 1996 Jul;174(1):26–33. doi: 10.1093/infdis/174.1.26. [DOI] [PubMed] [Google Scholar]
  5. Connor E. M., Sperling R. S., Gelber R., Kiselev P., Scott G., O'Sullivan M. J., VanDyke R., Bey M., Shearer W., Jacobson R. L. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173–1180. doi: 10.1056/NEJM199411033311801. [DOI] [PubMed] [Google Scholar]
  6. Erbelding E. J., Stanton D., Quinn T. C., Rompalo A. Behavioral and biologic evidence of persistent high-risk behavior in an HIV primary care population. AIDS. 2000 Feb 18;14(3):297–301. doi: 10.1097/00002030-200002180-00012. [DOI] [PubMed] [Google Scholar]
  7. Garcia P. M., Kalish L. A., Pitt J., Minkoff H., Quinn T. C., Burchett S. K., Kornegay J., Jackson B., Moye J., Hanson C. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999 Aug 5;341(6):394–402. doi: 10.1056/NEJM199908053410602. [DOI] [PubMed] [Google Scholar]
  8. Ghys P. D., Fransen K., Diallo M. O., Ettiègne-Traoré V., Coulibaly I. M., Yeboué K. M., Kalish M. L., Maurice C., Whitaker J. P., Greenberg A. E. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. AIDS. 1997 Oct;11(12):F85–F93. doi: 10.1097/00002030-199712000-00001. [DOI] [PubMed] [Google Scholar]
  9. Gupta P., Mellors J., Kingsley L., Riddler S., Singh M. K., Schreiber S., Cronin M., Rinaldo C. R. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol. 1997 Aug;71(8):6271–6275. doi: 10.1128/jvi.71.8.6271-6275.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hays R. B., Paul J., Ekstrand M., Kegeles S. M., Stall R., Coates T. J. Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among young gay and bisexual men who identify as HIV-negative, HIV-positive and untested. AIDS. 1997 Oct;11(12):1495–1502. doi: 10.1097/00002030-199712000-00014. [DOI] [PubMed] [Google Scholar]
  11. Higgins D. L., Galavotti C., O'Reilly K. R., Schnell D. J., Moore M., Rugg D. L., Johnson R. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA. 1991 Nov 6;266(17):2419–2429. [PubMed] [Google Scholar]
  12. Holtgrave D. R., Pinkerton S. D. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):54–62. doi: 10.1097/00042560-199709010-00009. [DOI] [PubMed] [Google Scholar]
  13. Jacquez J. A., Koopman J. S., Simon C. P., Longini I. M., Jr Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr. 1994 Nov;7(11):1169–1184. [PubMed] [Google Scholar]
  14. Janssen R. S., Satten G. A., Stramer S. L., Rawal B. D., O'Brien T. R., Weiblen B. J., Hecht F. M., Jack N., Cleghorn F. R., Kahn J. O. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998 Jul 1;280(1):42–48. doi: 10.1001/jama.280.1.42. [DOI] [PubMed] [Google Scholar]
  15. Kassler W. J., Dillon B. A., Haley C., Jones W. K., Goldman A. On-site, rapid HIV testing with same-day results and counseling. AIDS. 1997 Jul;11(8):1045–1051. doi: 10.1097/00002030-199708000-00014. [DOI] [PubMed] [Google Scholar]
  16. Kilmarx P. H., Hamers F. F., Peterman T. A. Living with HIV. Experiences and perspectives of HIV-infected sexually transmitted disease clinic patients after posttest counseling. Sex Transm Dis. 1998 Jan;25(1):28–37. doi: 10.1097/00007435-199801000-00007. [DOI] [PubMed] [Google Scholar]
  17. Lee T. H., Sakahara N., Fiebig E., Busch M. P., O'Brien T. R., Herman S. A. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1;12(4):427–428. doi: 10.1097/00042560-199608010-00015. [DOI] [PubMed] [Google Scholar]
  18. Little S. J., Daar E. S., D'Aquila R. T., Keiser P. H., Connick E., Whitcomb J. M., Hellmann N. S., Petropoulos C. J., Sutton L., Pitt J. A. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999 Sep 22;282(12):1142–1149. doi: 10.1001/jama.282.12.1142. [DOI] [PubMed] [Google Scholar]
  19. Lucas G. M., Chaisson R. E., Moore R. D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999 Jul 20;131(2):81–87. doi: 10.7326/0003-4819-131-2-199907200-00002. [DOI] [PubMed] [Google Scholar]
  20. Marks G., Burris S., Peterman T. A. Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility. AIDS. 1999 Feb 25;13(3):297–306. doi: 10.1097/00002030-199902250-00001. [DOI] [PubMed] [Google Scholar]
  21. May R. M., Anderson R. M. Transmission dynamics of HIV infection. Nature. 1987 Mar 12;326(6109):137–142. doi: 10.1038/326137a0. [DOI] [PubMed] [Google Scholar]
  22. Metzger D. S., Navaline H., Woody G. E. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998 Jun;113 (Suppl 1):97–106. [PMC free article] [PubMed] [Google Scholar]
  23. Miller C. J. Mucosal transmission of simian immunodeficiency virus. Curr Top Microbiol Immunol. 1994;188:107–122. doi: 10.1007/978-3-642-78536-8_6. [DOI] [PubMed] [Google Scholar]
  24. Mofenson L. M., Lambert J. S., Stiehm E. R., Bethel J., Meyer W. A., 3rd, Whitehouse J., Moye J., Jr, Reichelderfer P., Harris D. R., Fowler M. G. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999 Aug 5;341(6):385–393. doi: 10.1056/NEJM199908053410601. [DOI] [PubMed] [Google Scholar]
  25. Operskalski E. A., Stram D. O., Busch M. P., Huang W., Harris M., Dietrich S. L., Schiff E. R., Donegan E., Mosley J. W. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol. 1997 Oct 15;146(8):655–661. doi: 10.1093/oxfordjournals.aje.a009331. [DOI] [PubMed] [Google Scholar]
  26. Osmond D. H., Bindman A. B., Vranizan K., Lehman J. S., Hecht F. M., Keane D., Reingold A. Name-based surveillance and public health interventions for persons with HIV infection. Multistate Evaluation of Surveillance for HIV Study Group. Ann Intern Med. 1999 Nov 16;131(10):775–779. doi: 10.7326/0003-4819-131-10-199911160-00010. [DOI] [PubMed] [Google Scholar]
  27. Quinn T. C., Wawer M. J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., Meehan M. O., Lutalo T., Gray R. H. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000 Mar 30;342(13):921–929. doi: 10.1056/NEJM200003303421303. [DOI] [PubMed] [Google Scholar]
  28. Ragni M. V., Faruki H., Kingsley L. A. Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jan 1;17(1):42–45. doi: 10.1097/00042560-199801010-00006. [DOI] [PubMed] [Google Scholar]
  29. Rosenberg P. S., Biggar R. J. Trends in HIV incidence among young adults in the United States. JAMA. 1998 Jun 17;279(23):1894–1899. doi: 10.1001/jama.279.23.1894. [DOI] [PubMed] [Google Scholar]
  30. Samet J. H., Freedberg K. A., Stein M. D., Lewis R., Savetsky J., Sullivan L., Levenson S. M., Hingson R. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med. 1998 Apr 13;158(7):734–740. doi: 10.1001/archinte.158.7.734. [DOI] [PubMed] [Google Scholar]
  31. Shaffer N., Chuachoowong R., Mock P. A., Bhadrakom C., Siriwasin W., Young N. L., Chotpitayasunondh T., Chearskul S., Roongpisuthipong A., Chinayon P. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999 Mar 6;353(9155):773–780. doi: 10.1016/s0140-6736(98)10411-7. [DOI] [PubMed] [Google Scholar]
  32. Shaffer N., Roongpisuthipong A., Siriwasin W., Chotpitayasunondh T., Chearskul S., Young N. L., Parekh B., Mock P. A., Bhadrakom C., Chinayon P. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 1999 Mar;179(3):590–599. doi: 10.1086/314641. [DOI] [PubMed] [Google Scholar]
  33. Sodora D. L., Gettie A., Miller C. J., Marx P. A. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses. 1998 Apr;14 (Suppl 1):S119–S123. [PubMed] [Google Scholar]
  34. Stetler H. C., Granade T. C., Nunez C. A., Meza R., Terrell S., Amador L., George J. R. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. AIDS. 1997 Mar;11(3):369–375. doi: 10.1097/00002030-199703110-00015. [DOI] [PubMed] [Google Scholar]
  35. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet. 2000 Apr 1;355(9210):1158–1159. [PubMed] [Google Scholar]
  36. Valdiserri R. O., Holtgrave D. R., West G. R. Promoting early HIV diagnosis and entry into care. AIDS. 1999 Dec 3;13(17):2317–2330. doi: 10.1097/00002030-199912030-00003. [DOI] [PubMed] [Google Scholar]
  37. Vernazza P. L., Gilliam B. L., Dyer J., Fiscus S. A., Eron J. J., Frank A. C., Cohen M. S. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS. 1997 Jul;11(8):987–993. [PubMed] [Google Scholar]
  38. Vernazza P. L., Gilliam B. L., Flepp M., Dyer J. R., Frank A. C., Fiscus S. A., Cohen M. S., Eron J. J. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS. 1997 Aug;11(10):1249–1254. doi: 10.1097/00002030-199710000-00008. [DOI] [PubMed] [Google Scholar]
  39. Wenger N. S., Kusseling F. S., Beck K., Shapiro M. F. Sexual behavior of individuals infected with the human immunodeficiency virus. The need for intervention. Arch Intern Med. 1994 Aug 22;154(16):1849–1854. [PubMed] [Google Scholar]
  40. Wiktor S. Z., Biggar R. J., Melbye M., Ebbesen P., Colclough G., DiGioia R., Sanchez W. C., Grossman R. J., Goedert J. J. Effect of knowledge of human immunodeficiency virus infection status on sexual activity among homosexual men. J Acquir Immune Defic Syndr. 1990;3(1):62–68. [PubMed] [Google Scholar]
  41. Zhang H., Dornadula G., Beumont M., Livornese L., Jr, Van Uitert B., Henning K., Pomerantz R. J. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med. 1998 Dec 17;339(25):1803–1809. doi: 10.1056/NEJM199812173392502. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES